Dr. Reddy’s Laboratories (RDY) Expected to Post Earnings on Wednesday

Dr. Reddy’s Laboratories (NYSE:RDY) is expected to be announcing its Q1 26/27 results before the market opens on Wednesday, July 22nd. Analysts expect the company to announce earnings of $0.0918 per share and revenue of $854.1960 million for the quarter. Interested persons may visit the the company’s upcoming Q1 26/27 earning summary page for the latest details on the call scheduled for Wednesday, July 22, 2026 at 10:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Dr. Reddy’s Laboratories had a net margin of 12.90% and a return on equity of 12.34%. The firm had revenue of $852.55 million for the quarter, compared to analyst estimates of $886.58 million. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $12.52 on Tuesday. Dr. Reddy’s Laboratories has a 12-month low of $12.19 and a 12-month high of $15.67. The business has a 50-day simple moving average of $13.59 and a two-hundred day simple moving average of $13.69. The company has a quick ratio of 1.34, a current ratio of 1.80 and a debt-to-equity ratio of 0.03. The stock has a market cap of $10.45 billion, a PE ratio of 21.58, a PEG ratio of 1.90 and a beta of 0.25.

Wall Street Analysts Forecast Growth

RDY has been the topic of several research reports. Weiss Ratings cut Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. The Goldman Sachs Group lowered shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce”.

Institutional Trading of Dr. Reddy’s Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of RDY. Russell Investments Group Ltd. raised its position in Dr. Reddy’s Laboratories by 803.8% during the 4th quarter. Russell Investments Group Ltd. now owns 3,091 shares of the company’s stock worth $43,000 after purchasing an additional 2,749 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Dr. Reddy’s Laboratories by 71.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after buying an additional 1,294 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter valued at about $66,000. Raymond James Financial Inc. acquired a new stake in shares of Dr. Reddy’s Laboratories in the second quarter valued at about $67,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Dr. Reddy’s Laboratories during the third quarter worth about $78,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India?based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost?effective generic treatments for branded drugs that have lost patent protection, along with in?house research into innovative molecule development.